National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Study of Tamoxifen and Raloxifene (STAR) Trial
    Posted: 07/27/2000    Updated: 09/12/2007
Related Pages
Breast Cancer Home Page 1
NCI's gateway for information about breast cancer.

U.S. Task Force: Chemoprevention of Breast Cancer 2
The U.S. Preventive Services Task Force has issued two recommendations concerning the use of prescription medicines such as tamoxifen in the prevention of breast cancer.

Estrogen Receptors, Tamoxifen, and Raloxifene 3
Describes the hormone estrogen and its receptor. Explains the relationship of estrogen and its receptor to breast cancer and the risks and benefits of reducing cancer risk with drugs called antiestrogens and selective estrogen receptor molecules (SERMs).
STAR Background

The following links will take you to press releases and other materials concerning the STAR trial that have been prepared by the National Cancer Institute's Office of Communications and Education.

In English
Results of the Study of Tamoxifen and Raloxifene (STAR) Released: Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer 4
(Posted: 04/17/2006, Updated: 06/21/2006) - Results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease. Questions and Answers 5, STAR en Español 6

STAR Results: Raloxifene as Effective as Tamoxifen, Better Safety Profile 7
Article from the Apr. 18, 2006, issue of the NCI Cancer Bulletin.

Major Breast Cancer Prevention Study Enters Final Stretch 8
Article from the Mar. 9, 2004, issue of the NCI Cancer Bulletin.
En Español
Difusión de resultados iniciales del Estudio del Tamoxifeno y del Raloxifeno (STAR): el fármaco para el tratamiento de la osteoporosis, raloxifeno, es tan efectivo como el Tamoxifeno en la prevención de cáncer de seno invasor 9
(Publicación: 04/17/2006) - Los resultados iniciales del Estudio del Tamoxifeno y del Raloxifeno, STAR, demuestran que el fármaco raloxifeno, actualmente utilizado para prevenir y tratar la osteoporosis en mujeres posmenopáusicas, funciona tan bien como el tamoxifeno para reducir el riesgo de cáncer de seno entre las mujeres posmenopáusicas que tienen riesgo elevado de padecer la enfermedad. Preguntas y respuestas 10
En Français
Les premiers résultats de l'étude STAR (Study of Tamoxifen and Raloxifene) 11
Les premiers résultats de l'étude STAR (Study of Tamoxifen and Raloxifene) montrent que le raloxifène, habituellement utilisé dans la prévention et le traitement de l'ostéoporose chez la femme ménopausée, est aussi efficace que le tamoxifène à réduire le risque de cancer du sein chez la femme ménopausée déjà à risque.


Table of Links

1http://www.cancer.gov/cancertopics/types/breast
2http://redir.nci.nih.gov/cgi-bin/redir.pl?section=Clinicaltrials&destURI=http%3
a%2f%2fwww.ahrq.gov%2fclinic%2f3rduspstf%2fbreastchemo%2f
3http://www.cancer.gov/cancertopics/understandingcancer/estrogenreceptors
4http://www.cancer.gov/newscenter/pressreleases/STARresultsApr172006
5http://www.cancer.gov/newscenter/pressreleases/STARresultsQandA
6http://www.cancer.gov/newscenter/pressreleases/STARresultsSpanish
7http://www.cancer.gov/ncicancerbulletin/NCI_Cancer_Bulletin_041806/page2
8http://www.cancer.gov/ncicancerbulletin/NCI_Cancer_Bulletin_030904/page2
9http://www.cancer.gov/espanol/noticias/estudio-clinico-STAR-resultados
10http://www.cancer.gov/newscenter/pressreleases/STARresultsQandASpanish
11http://redir.nci.nih.gov/cgi-bin/redir.pl?section=Clinicaltrials&destURI=http%3
a%2f%2ffoundation.nsabp.org%2fMedia%2fSTAR_results_french.pdf